Evidence mapPaperPMID 39724243Full record

ReviewArchives of microbiology2024

Breaking the resistance: integrative approaches with novel therapeutics against Klebsiella pneumoniae.

Vimarishi Koul, Akshi Sharma, Diksha Kumari, Vishwani Jamwal, Tashi Palmo, Kuljit Singh

Abstract readReview
PubMed Publisher
In one paragraph

Review in Archives of microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Vimarishi Koul *Infectious Diseases Division, CSIR- Indian Institute of Integrative Medicine, Jammu, 180001, India.
Akshi Sharma *Infectious Diseases Division, CSIR- Indian Institute of Integrative Medicine, Jammu, 180001, India.
Diksha KumariInfectious Diseases Division, CSIR- Indian Institute of Integrative Medicine, Jammu, 180001, India.
Vishwani JamwalInfectious Diseases Division, CSIR- Indian Institute of Integrative Medicine, Jammu, 180001, India.
Tashi PalmoInfectious Diseases Division, CSIR- Indian Institute of Integrative Medicine, Jammu, 180001, India.
Kuljit SinghInfectious Diseases Division, CSIR- Indian Institute of Integrative Medicine, Jammu, 180001, India. singh.kuljit@iiim.res.in.

Funding

CSIR-R&D Seed Fund (RDSF) CSPS24/RDSF/IIIM/IHP24/03
6 · The paper itself

Abstract

Klebsiella pneumoniae is a leading cause of anti-microbial resistance in healthcare-associated infections that have posed a severe threat to neonatal and wider community. The escalating crises of antibiotic resistance have compelled researchers to explore an innovative arsenal beginning from natural resources to chemical modifications in order to overcome the ever-increasing resistance issues. The present review highlights the drug discovery efforts with a special focus on cutting-edge strategies in the hunt for potential drug candidates against MDR/XDR Klebsiella pneumoniae. Nature's bounty constituting plant extracts, essential oils, fungal extracts, etc. holds promising anti-bacterial potential especially when combined with existing antibiotics. Further, enhancing these natural products with synthetic moieties has improved their effectiveness, creating a bridge between the natural and synthetic world. Conversely, the synthetically modified novel scaffolds have been also designed to meticulously target specific sites. Furthermore, we have also elaborated various emerging strategies for broad-spectrum infections caused by K. pneumoniae, which include anti-microbial peptides, nanotechnology, drug repurposing, bacteriophage, photodynamic, and multidrug therapies. This review further addresses the challenges confronted by the research community and the future way forward in the field of drug discovery against multi-resistant bacterial infections.

Indexed as

Anti-Bacterial AgentsDrug Resistance, Multiple, BacterialKlebsiella InfectionsKlebsiella pneumoniaeBiological ProductsDrug DiscoveryDrug RepositioningHumansAnti-Bacterial AgentsBiological ProductsAnti-microbial peptidesAnti-microbial resistanceESKAPE pathogensKlebsiella pneumoniaeNatural productsTherapeutics

Identifiers

PMID39724243

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.